Novartis Lp(a) Drug Lowers the Biomarker But Fails to Cut Heart Attacks or Strokes
A Phase III trial of 8,000+ patients found pelacarsen reduced Lp(a) levels but did not cut cardiovascular events, challenging a key longevity assumption.
Summary
Novartis and Ionis Pharmaceuticals' drug pelacarsen successfully lowered Lp(a) — a genetically inherited cholesterol-like particle linked to early heart disease — but failed to reduce heart attacks, strokes, or cardiovascular deaths in a Phase III trial of over 8,000 high-risk patients. Lp(a) affects roughly one in five people, is largely unaffected by diet or exercise, and had no approved targeted therapy before this trial. The result is a significant setback not just for this drug but for the broader scientific assumption that lowering a cardiovascular biomarker automatically translates into better outcomes. Full trial data are yet to be presented, and researchers may find benefit in specific subgroups with very high Lp(a) levels.
Detailed Summary
Pelacarsen, an antisense drug developed by Novartis and Ionis Pharmaceuticals, was designed to directly lower lipoprotein(a), or Lp(a) — a genetically determined particle that carries cholesterol into artery walls and promotes clotting. Elevated Lp(a) affects about one in five people and is almost entirely inherited, making it resistant to lifestyle changes. Nearly a third of people who develop heart disease at a young age have high Lp(a), yet until now no drug had been approved to specifically target it.
The Phase III Lp(a)HORIZON trial enrolled 8,323 patients who already had elevated Lp(a) and established heart disease, all on standard guideline-directed care. Pelacarsen did lower Lp(a) levels as intended. However, it failed to reduce the primary composite endpoint of cardiovascular death, heart attack, stroke, or urgent artery procedures compared with placebo. Novartis acknowledged the disappointing result while noting the trial advances scientific understanding of the Lp(a)-cardiovascular risk relationship.
The miss carries implications well beyond a single drug pipeline. For years, longevity and cardiovascular researchers have operated on the assumption that correcting an abnormal biomarker translates into reduced clinical risk — a logic that has guided enormous investment in Lp(a)-targeting therapies. This trial puts that assumption under scrutiny. Lp(a) seemed like a near-perfect test case: genetic, measurable with one blood test, and now biochemically modifiable. The fact that lowering the number did not move outcomes is a meaningful signal.
Other companies are pursuing Lp(a) via different molecular mechanisms, and this result will not halt those efforts. However, it is likely to slow regulatory and commercial timelines and raise the evidentiary bar for future Lp(a) drugs.
Full data have not yet been presented at a medical congress, so subgroup analyses — particularly in patients with very high Lp(a) — may reveal pockets of benefit not visible in the overall population. Clinicians and patients monitoring Lp(a) should await those findings before drawing final conclusions about the biology.
Key Findings
- Pelacarsen lowered Lp(a) levels in all treated patients but did not reduce heart attacks, strokes, or cardiovascular deaths.
- The Phase III Lp(a)HORIZON trial enrolled 8,323 high-risk patients already on optimized standard-of-care medications.
- About 1 in 5 people carry elevated Lp(a), which is largely genetic and unresponsive to diet or exercise.
- The failure challenges the assumption that correcting a cardiovascular biomarker automatically reduces clinical risk.
- Full data and possible subgroup benefits are still pending presentation at a medical congress.
Methodology
This is a news report summarizing a Phase III randomized controlled trial (Lp(a)HORIZON, n=8,323) from Longevity.Technology, a credible longevity-focused outlet. The report draws on Novartis' official announcement and executive statements; full peer-reviewed data have not yet been published or presented at a medical congress.
Study Limitations
Full trial data and peer-reviewed publication are not yet available, limiting independent analysis. Subgroup results — especially in patients with very high Lp(a) — have not been reported and could alter interpretation. The article relies on corporate press statements, which may emphasize selected findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: